Recent Updates
Recently added Catalysts
SANA Negative Sentiment Score: 20/100

SANA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Key Takeaway: A class action lawsuit has been initiated against Sana Biotechnology, Inc. by Bronstein, Gewirtz & Grossman, LLC, alleging that the company and its officers made misleading statements regarding the company's financial health and product pipeline between March 2023 and November 2024. Investors are urged to join the lawsuit to recover losses incurred during this period, with specific claims regarding insufficient operational funds and overstatements about product prospects. The firm emphasizes representation on a contingency fee basis, ensuring no upfront costs to investors.

Market Sentiment Analysis

CONCERNS & RISKS

  • Class action lawsuit filed against Sana for alleged securities law violations.
  • Claims that Sana misled investors about its financial stability and operational capacity.
  • Concerns regarding potential discontinuation of key product candidates due to financial issues.
  • Allegations of materially false statements affecting investor trust and share value.

Full Press Release Details

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. (“Sana” or “the Company”) (NASDAQ: SANA) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/SANA.
The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding Sana's business, operations, and prospects. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) Sana was at significant risk of having insufficient funds to maintain its current operations and advance one or more of its product candidates; (2) SC291 in oncology, SC379, and SG299 were less promising than Defendants had led investors to believe; (3) in order to preserve cash and advance its more promising product candidates, Sana was likely to decrease funding for and/or discontinue SC291 in oncology, SC379, and SG299, as well as significantly reduce its headcount; (4) accordingly, Defendants overstated Sana's financial capacity to maintain its current operations and advance its existing product candidates; and (5) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/SANA. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Sana you have until May 20, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com

Tags

Frequently Asked Questions

What is the class action lawsuit against Sana Biotechnology about?

The lawsuit alleges Sana made false statements about its finances and product candidates.

Who can join the class action lawsuit?

Any investor who acquired Sana securities between March 17, 2023, and November 4, 2024.

What is the deadline to become a lead plaintiff?

Investors must request lead plaintiff status by May 20, 2025.

Is there a cost to join the class action?

No, representation is on a contingency fee basis; no cost unless successful.

How has Bronstein, Gewirtz & Grossman performed for investors?

The firm has recovered hundreds of millions for investors in securities fraud cases.

Last updated: May 15, 2025